Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 20, Issue 3, 2011, Pages 234-241

  Ho, Josephine ^a   Panagiotopoulos, Constadina ^a   Mccrindle, Brian ^a   Grisaru, Silviu ^a   Pringsheim, Tamara ^a  

^a CAMESA guideline group ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DEXAMPHETAMINE; DEXFENFLURAMINE; FAMOTIDINE; FLUOXETINE; FLUVOXAMINE; GLUCOSE; INSULIN; METFORMIN; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PHENYLPROPANOLAMINE; PLACEBO; PROLACTIN; QUETIAPINE; REBOXETINE; RISPERIDONE; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THYROTROPIN; TOPIRAMATE; TRIACYLGLYCEROL; UNINDEXED DRUG; ZIPRASIDONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MENTAL DISEASE; METABOLIC DISORDER; PROLACTIN BLOOD LEVEL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THYROID DISEASE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80051660261     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Alfaro, C. L., Wudarsky, M., Nicolson, R., Gochman, P., Sporn, A., Lenane, M., & Rapoport, J. (2002). Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of Child and Adolescent Psychopharmacology, 12(2), 83-91.
2. Alvarez-Jimenez, M., Gonzalez-Blanch, C., Vazquez-Barquero, J. L., Perez-Iglesias, R., Martinez-Garcia, O., Perez-Pardal, T., Crespo-Facorro, B. (2006). Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. Journal of Clinical Psychiatry, 67(8), 1253-1260.
3. Arman, S., Sadramely, M. R., Nadi, M., & Koleini, N. (2008). A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal, 29(8), 1130-1134.
4. Brozek, J. L., Akl, E. A., Alonso-Coello, P., & et al. (2009). Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy, 64(5), 669-677.
5. Brozek, J. L., Akl, E. A., Alonso-Coello, P., Lang, D., Jaeschke, R., Williams, J. W., GRADE Working Group. (2009). Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy, 64(5), 669-677.
6. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2008). Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes, 32(Suppl 1), S1-S201.
7. Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association, 302(16), 1765-1773.
8. Daniels, S. R., & Greer, F. R. (2008). Lipid screening and cardiovascular health in childhood. Pediatrics, 122(1), 198-208.
9. Douketis, J. D., Paradis, G., Keller, H., & Martineau, C. (2005). Canadian guidelines for body weight classification in adults: Application in clinical practice to screen for overweight and obesity and to assess disease risk. Canadian Medical Association Journal, 172(8), 995-998.
10. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents (2004). Pediatrics, 114(2 Suppl 4th Report), 555-576.
11. Haas, M., Eerdekens, M., Kushner, S., Singer, J., Augustyns, I., Quiroz, J., Kusumakar, V. (2009). Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. British Journal of Psychiatry, 194(2), 158-164.
12. Haddad, P. M., & Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs, 64(20), 2291-2314.
13. A health professional's guide to using growth charts (2004). Paediatrics and Child Health, 9(3), 174-188.
14. Kavey, R. E., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Steinberger, J. (2006). Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation, 114(24), 2710-2738.
15. Khazaal, Y., Fresard, E., Rabia, S., Chatton, A., Rothen, S., Pomini, V., Zullino, D. (2007). Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophrenia Research, 91(1-3), 169-177.
16. Klein, D. J., Cottingham, E. M., Sorter, M., Barton, B. A., & Morrison, J. A. (2006). A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry, 163(12), 2072-2079.
17. Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M. (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology, 19(1), 57-61.
18. Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009). Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Systemic Review, (4), CD006627.
19. Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., De Thomas, C., Kafantaris, V., Kane J. (2008). Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biological Psychiatry, 63(5), 524-529.
20. Lau, D. C., Douketis, J. D., Morrison, K. M., Hramiak, I. M., Sharma, A. M., & Ur, E. (2007). 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. Canadian Medical Association Journal, 176(8), S1-13.
21. Lee, B. H., Kim, Y. K., & Park, S. H. (2006). Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Progress in Neuropsychopharmacology & Biological Psychiatry, 30(4), 714-717.
22. Lindsay, R. L., Leone, S., & Aman, M. G. (2004). Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clinical Pediatrics (Philadelphia), 43(5), 437-444.
23. Maayan, L., Vakhrusheva, J., & Correll, C. (2010). Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology, 35(7), 1520-1530.
24. McCrindle, B. W. (in press). Pathogenesis and management of obesity-related dyslipidemia. New York, NY: Humana Press.
25. McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Daniels, S. (2007). Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation, 115(14), 1948-1967.
26. Morrison, J. A., Cottingham, E. M., & Barton, B. A. (2002). Metformin for weight loss in pediatric patients taking psychotropic drugs. American Journal of Psychiatry, 159(4), 655-657.
27. Oude Luttikhuis, H., Baur, L., Jansen, H., Shrewsbury, V. A., O'Malley, C., Stolk, R. P., & Summerbell, C. (2009). Interventions for treating obesity in children. Cochrane Database Systemic Review, (1), CD001872.
28. Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry, 163(3), 402-410.
29. Roke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K. (2009). Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology, 19(4), 403-414.
30. Shin, L., Bregman, H., Breeze, J. L., Noyes, N., & Frazier, J. A. (2009). Metformin for weight control in pediatric patients on atypical antipsychotic medication. Journal of Child and Adolescent Psychopharmacology, 19(3), 275-279.
31. Weber, M., & Wyne, K. (2006). A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research, 83(1), 95-101.